Atara biotherapeutics provides update on strategic collaboration with bayer

South san francisco, calif.--(business wire)--atara biotherapeutics, inc. (nasdaq: atra), a leader in t-cell immunotherapy, leveraging its novel allogeneic ebv t-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today announced that it received notification of bayer's intention to end the exclusive worldwide licensing agreement for next-generation mesothelin-directed car t-cell therapies. the collaboration included the funding and development of
ATRA Ratings Summary
ATRA Quant Ranking